SN//Connect

Addressing Racial Disparities in Health Care

Latest News

Patients Need Careful Monitoring for CAR T-Cell Therapy Side Effects

Chimeric antigen receptor (CAR) T-cell therapy has become a major ally in the treatment of certain lymphomas and leukemias. However, this therapy is not without risks.

Learn More

The Promise of CAR T-Cell Therapy for Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, with response rates in studies of 85% or more, and about half of patients going into complete remission for a year or longer.

Learn More

Cytokine Release Syndrome: The Downside of CAR T-Cell Therapy

Chimeric antigen receptor (CAR) T-cell therapy has had great success thus far, producing lasting responses and even remissions in patients with relapsed or refractory hematologic cancers such as B-cell lymphoma and acute lymphoblastic leukemia (ALL).

Learn More

PARP Inhibitors Boost Survival in Ovarian Cancer, Prompting New ASCO Guidelines on Their Use

PARP inhibitors are a class of drugs that inhibit one of the backup systems of DNA damage repair. Ovarian cancers with BRCA1, BRCA2, or certain other mutations have a defect in a major DNA damage repair pathway and are highly dependent on secondary pathways for their survival.

Learn More

Delaying Treatment to Protect Ovarian Cancer Patients from COVID Has Benefits and Risks

Determining the most appropriate cancer treatment for your patients usually involves finding a delicate balance between the risks and benefits. How effective will the treatment be? Can a patient tolerate it? COVID adds one more factor into the equation.

Learn More

COVID-19 Has Shifted Much of Ovarian Cancer Care to Telemedicine

COVID-19 has shifted much of oncology practice from the medical office to the computer screen. Fear of infection in an already vulnerable population has led to the rapid expansion of remote care delivery. When ovarian cancer visits are done remotely, do patients lose out?

Learn More

In Head-to-Head Matchup with KRd, VRd Remains Gold Standard of Care in Multiple Myeloma

The three-drug combination of bortezomib, lenalidomide, and dexamethasone (VRd) has been the standard therapy for patients with newly diagnosed multiple myeloma. The ENDURANCE trial presented at ASCO was a head-to-head effort to determine whether adding the next-generation proteasome inhibitor on the block, carfilzomib, to lenalidomide and dexamethasone (KRd) might perform even better. In short, it didn't.

Learn More

CAR T-Cell Therapy Produces ‘Remarkable’ Results in Multiple Myeloma, but It’s Still Not a Cure

Chimeric antigen receptor (CAR) T-cell therapy is showing great promise in multiple myeloma, as evidenced by a trio of investigational therapies presented at this year's ASCO conference. 

Learn More